Harnessing RNAi Nanomedicine for Manipulating Lymphocyte Function

In this webinar, Professor Dan Peer from Tel Aviv University will talk about the application of microfluidics for the preparation of targeted lipid nanoparticles entrapping siRNAs (RNA-tLNPs) directed towards lymphocytes . Special emphasis will be made on the ability to conjugate different ligands and monoclonal antibodies to the surface of LNPs to endow them with targeting capabilities. Examples will focus on T cells and malignant B cells and describe how RNA-tLNPs can be utilized for therapeutic gene silencing in hematological B cell malignancies and as a tool to study leukocyte biology.

NanoAssemblr™ Blaze™ | Dr. Peter Johnson, PNI Tech Talk

NanoAssemblr™ Blaze™ Tech Talk during the 2016 PNI Nanomedicines Symposium

NanoAssemblr™ Spark™ | Tim Leaver, PNI Tech Talk

NanoAssemblr™ Spark™ Tech Talk from 2016 PNI Nanomedicine Symposium

NanoAssemblr™ Formulation Kits | Dr. Shell Ip, PNI Tech Talk

NanoAssemblr™ Formulation Kits

NanoAssemblr™ Benchtop | Dr. Gesine Heuck, PNI Tech Talk

NanoAssemblr™ Benchtop Tech Talk from 2016 Nanomedicine Symposium

Microfluidic Production of Liposomes | Yvonne Perrie, Strathclyde

Microfluidic production of liposomes - from low solubility drugs to vaccines.

Targeted mRNA delivery to the Liver for I-ERT | Pierrot Harvie, PhaseRX

Targeted mRNA delivery to the Liver for Intracellular Enzyme Replacement Therapy | Pierrot Harvie, PhaseRX

Liposomes: from Prototype to the Clinic | Norbert Maurer, Transferra Nanosciences

Liposomes: from Prototype to the Clinic | Norbert Maurer, Transferra Nanosciences

Microfluidics in manufacturing of mRNA Nanomedicines | Heinrich Haas, BioNTech

Microfluidics in manufacturing of mRNA Nanomedicines | Heinrich Haas, BioNTech

Preparation of nano droplets for ultrasound theranostics by using the NanoAssemblr | Kazuo Maruyama,

Preparation of nano droplets for ultrasound theranostics by using the NanoAssemblr | Kazuo Maruyama, Teikyo University 

NanoAssemblr™ GMP Scale-Up System | Ray Lockard, Precision NanoSystems

NanoAssemblr™ GMP Scale-Up System | Ray Lockard, Precision NanoSystems

Self-assembled Polymeric Nanoparticles for Drug Targeting to Tumors

Dr. Shyh-Dar Li from the University of British Columbia introduced the design, synthesis and fabrication of a self-assembled polymeric nanoparticle system, and the use of which to deliver insoluble anticancer drugs for therapy of tumors in preclinical models.

Microfluidic Strategies to Improve Encapsulation of Hydrophobic Drugs in Nanoparticles

Microfluidic-mediated self-assembly of liposomes and polymer nanoparticles expands the strategies available to the formulation scientist for the encapsulation and delivery of hydrophobic compounds. In this webinar Dr. James Taylor and Dr. Shyam Garg will explore the encapsulation of a model hydrophobic drug, Coumarin-6, by PLGA nanoparticles and cholesterol-containing liposomes. Microfluidic process parameters and nanoparticle compositions will be investigated, and their influence on particle size, polydispersity and encapsulation efficiency will be discussed.

Lipids for Liposomes: Selection, Preparation and Application | Di Bush, Avanti Polar Lipids

Lipids for Liposomes: Selection, Preparation and Application | Di Bush, Avanti Polar Lipids

Improved CRISPR Genome Editing using crRNA:tracrRNA complexes and Cas9 | Ashley Jacobi, IDT

Improved CRISPR Genome Editing using crRNA:tracrRNA complexes and Cas9 | Ashley Jacobi, IDT

Lipid Particle Formation Processes using Microfludic Mixing| Ben Boyd, Monash University

in situ Interrogation of structured Lipid Particle Formation Processes using Microfludic Mixing Devices | Ben Boyd, Monash University

NanoAssemblr Benchtop Instrument

A demonstration of the manufacture of nanoparticles using the NanoAssemblr Benchtop Instrument.

Precision NanoSystems' Technology

Precision NanoSystems - NanoAssemblr™ Platform
Accelerating the Development of Nanomedicines
Microfluidics enables the manufacture of nanoparticles that would be difficult or even impossible to develop through an alternative method.

Formulating Nanomedicines: Current Challenges and Solutions

Nanomedicines are a promising treatment modality for the targeted delivery and controlled release of therapeutic agents. To fully achieve the potential of nanomedicines there is a need to improve the reproducibility and scalability of production methods. 

Join Dr. Gesine Heuck for this informative webinar as she reviews the basic principles of lipid-based nanoparticle production, challenges to producing nanomedicines, as well as methods currently available for nanomedicine production with specific focus on lipid nanoparticles and liposomes. 

This is the first in our series of 30-minute webinars exploring nanomedicine manufacture. Future webinars in this series will focus on other types of nanoparticles as well as a more in-depth discussions of our technology.

Application of Microfluidic Mixing for Generating Limit Size Nanoparticles

In this webinar, Professor Pieter Cullis from the University of British Columbia will unpack the application of microfluidics for the preparation of "limit-size" lipid nanoparticle systems including liposomes, nanoemulsions and RNA-lipid nanoparticles (RNA-LNP). "Limit size" is defined as the smallest energetically and thermodynamically stable structure possible based on the packing constraints of the component molecules. Smaller lipid nanoparticle systems can impact the activity of their payloads by altering biodistribution for example by penetrating deeper into solid tumors. Also, smaller systems are amenable to alternative administration routes such as subcutaneous injection. 

Join us for this exploration as we are excited to present our first collaborative webinar in our series about LNP systems manufactured using microfluidics.

Lipid nanoparticle delivery of siRNA to unravel chronic pain

In this webinar, Dr. Marc-Andre Dansereau from the Université de Sherbrooke will describe how RNAi was used to better understand how the CCL2 chemokine and its receptor, CCR2, contribute to the development of chronic pain. Altough CCR2 has been identified as an interesting target for the development of a new class of analgesic drug, its regulation in the context of chronic pain is still widely unknown.​ 

Injecting Dicer-substrate siRNA against CCL2 or CCR2 encapsulated in lipid nanoparticles (LNP) into the intrathecal space after the induction of chronic inflammatory pain in rats revealed a biphasic contribution of this chemokine system, as well as a differential role of dorsal root ganglia-derived CCL2 and CCR2.

Please reload

LinkedIn Dr. Golik Scientific Solutions
Dr. Golik Logo

Copyrights © Dr. Golik All rights reserved 2019